A carregar...
P17.83 OUTCOMES OF RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB AT A TERTIARY CARE CENTER
BACKGROUND: Bevacizumab is FDA approved for use in recurrent glioblastoma (rGBM). There is limited information on outcomes of rGBM treated with bevacizumab at tertiary care hospitals. We evaluated the progression-free survival (PFS) and overall survival (OS) in rGBM patients treated with bevacizumab...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4185786/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.412 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|